William Parks is a Game Rant editor from the USA. Upon graduating from the University of Southern California’s School of Cinematic Arts, William entered the realm of fine arts administration, ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

OpenAI is testing a new model for Codex called "GPT-5.2-Codex-Max." Some users have spotted a new model, GPT-5.2-Codex-Max, when they ask Codex what model it is using. OpenAI rolled out Codex with GPT ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

What if the future of artificial intelligence wasn’t just about incremental improvements but a complete redefinition of what’s possible? Enter GPT 5.2, the AI model that has shattered expectations and ...

What if the future of work wasn’t just faster, but smarter, effortlessly blending creativity, technical precision, and strategic insight? OpenAI’s latest release, ChatGPT 5.2, promises to redefine ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...